I think the worm turns in about 2 weeks and from then to the first of the year we get some news at fairly regular intervals should mgt want to work it that way. Early Nov B-OM top line, late Nov UP/UPS end results, early to mid Dec K-OC interim data, and very late Dec to very early Jan P top line results. The aforementioned is just a scenario of how I would most likely play out the news, what happens most likely will turn out totally different.

All of this news should cause many media avenues to start taking a look at IPIX and possibly some decent reports in publications or other video spots to focus more attention on IPIX and the strength of it's pipeline and the many medical issues our trials are addressing.

Note I don't mention anything about partnerships, deals, licensees, etc. That would be the supreme icing on the cake, but IMO it is still too early for a decent deal Q4. If one does occur, it will have to be huge as it only happens if a BP steps up to the plate and pulls the trigger for a massive deal to acquire a complete platform for one of our drugs. I sincerely hope for a major deal in Q1 '18 but I am not putting any time line when one should be expected. When Leo gets a good deal, we will hear about it. Til then, we wait while he negotiates.

I feel the strength of our news in Q4 will be able to shut down the FUD that will occur if a deal does not happen in 2017.

Really enjoying the low volume days and the realization that those shorting the company are finding themselves in a situation that daily gets more dire for them.